Autor: "Mahmoud, Remi" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Letter: loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply.
Autorzy:: Mahmoud R; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Schultheiss JPD; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Fidder HH; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Oldenburg B; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Feb; Vol. 55 (4), pp. 499-500.
Typ publikacji:: Letter; Comment
MeSH Terms:: Duration of Therapy*
Inflammatory Bowel Diseases*/drug therapy
Chronic Disease ; Humans

Opinia redakcyjna

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases - the longer the less? Authors' reply.
Autorzy:: Schultheiss JPD; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Mahmoud R; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Fidder HH; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Oldenburg B; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Jan; Vol. 55 (2), pp. 246.
Typ publikacji:: Editorial; Comment
MeSH Terms:: Inflammatory Bowel Diseases*/drug therapy
Humans

Opinia redakcyjna

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease.
Autorzy:: Schultheiss JPD; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Mahmoud R; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Louwers JM; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
van der Kaaij MT; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
van Hellemondt BP; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
van Boeckel PG; Division of Internal Medicine, Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Mahmmod N; Division of Internal Medicine, Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Jharap B; Division of Internal Medicine, Department of Gastroenterology and Hepatology, Meander Medical Centre, Amersfoort, The Netherlands.
Fidder HH; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Oldenburg B; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Nov; Vol. 54 (10), pp. 1298-1308. Date of Electronic Publication: 2021 Sep 24.
Typ publikacji:: Journal Article; Multicenter Study
MeSH Terms:: Colitis, Ulcerative*/drug therapy
Crohn Disease*
Inflammatory Bowel Diseases*/drug therapy
Adalimumab/therapeutic use ; Duration of Therapy ; Humans ; Infliximab ; Male ; Retrospective Studies ; Tumor Necrosis Factor-alpha

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model.
Autorzy:: Mahmoud R; University Medical Centre Utrecht, Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands.
van Lieshout C; University Medical Centre Utrecht, Julius Centre for Health Sciences and Primary Care, Department of Health Technology Assessment, Utrecht, The Netherlands.
Frederix GWJ; University Medical Centre Utrecht, Julius Centre for Health Sciences and Primary Care, Department of Health Technology Assessment, Utrecht, The Netherlands.
Jharap B; Meander Medical Centre, Division of Internal Medicine, Department of Gastroenterology and Hepatology, Amersfoort, The Netherlands.
Oldenburg B; University Medical Centre Utrecht, Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2021 May 04; Vol. 15 (5), pp. 709-718.
Typ publikacji:: Comparative Study; Journal Article
MeSH Terms:: Cost-Benefit Analysis*
Antibodies, Monoclonal/*economics
Biosimilar Pharmaceuticals/*economics
Colitis, Ulcerative/*drug therapy
Gastrointestinal Agents/*economics
Infliximab/*economics
Protein Kinase Inhibitors/*economics
Adalimumab/administration & dosage ; Adalimumab/economics ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/economics ; Biosimilar Pharmaceuticals/administration & dosage ; Gastrointestinal Agents/administration & dosage ; Humans ; Infliximab/administration & dosage ; Markov Chains ; Piperidines/administration & dosage ; Piperidines/economics ; Protein Kinase Inhibitors/administration & dosage ; Pyrimidines/administration & dosage ; Pyrimidines/economics ; Quality-Adjusted Life Years ; Recurrence ; Remission Induction ; Ustekinumab/administration & dosage ; Ustekinumab/economics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root.
Autorzy:: Mahmoud R; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands.
Itzkowitz SH; Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Jan; Vol. 53 (2), pp. 335-336.
Typ publikacji:: Editorial; Comment
MeSH Terms:: Colitis*
Colorectal Neoplasms*/diagnosis
Inflammatory Bowel Diseases*/complications
Inflammatory Bowel Diseases*/diagnosis
Humans

Opinia redakcyjna

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Mahmoud, Remi"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język